報價延遲最少15分鐘:2026/06/03 07:42 EDT
盤前時段
|
||||
|
1.52 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.52
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.64/-0.78
|
|
企業價值
280.68M
|
| 資產負債 |
|
每股賬面淨值
0.51
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
42.17M
|
|
每股收益
1.37
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems. |
